Article
Oncology
Seema A. Khan, Fengmin Zhao, Lori J. Goldstein, David Cella, Mark Basik, Mehra Golshan, Thomas B. Julian, Barbara A. Pockaj, Christine A. Lee, Wajeeha Razaq, Joseph A. Sparano, Gildy Babiera, Irene A. Dy, Sarika Jain, Paula Silverman, Carla S. Fisher, Amye J. Tevaarwerk, Lynne Wagner, George W. Sledge
Summary: Early locoregional therapy for the primary site did not improve survival in patients with metastatic breast cancer, but it was associated with improved locoregional control without impacting overall quality of life.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Seema Ahsan Khan, Steven Schuetz, Omid Husseini
Summary: The current evidence fails to support the effectiveness of the paradigm guiding the management of de novo metastatic breast cancer.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Xueyang Hu, Wenjun Chen, Fanfan Li, Pengfei Ren, Hongyang Wu, Congjun Zhang, Kangsheng Gu
Summary: This study investigated the altered expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and cell proliferation index (Ki-67) in primary and metastatic breast cancer lesions, and their correlation with clinicopathological factors and disease-free survival (DFS). The expression rates of ER, PR, HER2, and Ki-67 were inconsistent between primary and metastatic lesions. The size of the primary lesion was not correlated with altered receptor expression, but lymph node metastasis was. Patients with positive ER and PR expression in both primary and metastatic lesions had the longest DFS, while patients with negative expression had the shortest DFS. Changes in HER2 expression did not affect DFS. Patients with low Ki-67 expression had longer DFS than those with high expression. These findings suggest that the heterogeneity of ER, PR, HER2, and Ki-67 expression has important implications for treatment and prognosis.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Yang Li, Shuaibing Wang, Wenbo Yang, Hong Liu
Summary: The study found that the survival of breast cancer patients is associated with molecular subtypes, metastatic sites, and primary tumor surgery. Patients with hormone receptor positive/HER2 positive subtype showed the best survival time, while triple negative patients showed the worst survival time.
Review
Oncology
Guillermo Villacampa, Andri Papakonstantinou, Irma Fredriksson, Alexios Matikas
Summary: This study found that surgery of the primary tumor in cases of de novo metastatic breast cancer does not prolong patient survival, except possibly in younger/premenopausal patients. Therefore, breast surgery should be conducted within the context of clinical trials.
Article
Oncology
Marcia A. Inda, Paul van Swinderen, Anne van Brussel, Cathy B. Moelans, Wim Verhaegh, Hans van Zon, Eveline den Biezen, Jan Willem Bikker, Paul J. van Diest, Anja van de Stolpe
Summary: Personalized breast cancer treatment with targeted therapy requires identification of responder patients. Phenotypical heterogeneity within the primary tumor and between primary tumor and metastases may affect therapy response, suggesting analysis of metastatic samples for late stage patients is important. Targeted therapy based on analysis of one primary tumor biopsy may not fully represent the heterogeneity within and between tumors, highlighting the need for further analysis of metastatic biopsies.
Article
Oncology
Nadeem Bilani, Leah Elson, Hong Liang, Elizabeth Blessing Elimimian, Zeina Nahleh
Summary: This large retrospective study revealed that clinicopathologic characteristics and social determinants were associated with the use of surgery in patients with de novo metastatic breast cancer, and surgery, particularly resection of the primary tumor and distant site resection, significantly improved overall survival.
CLINICAL BREAST CANCER
(2021)
Article
Multidisciplinary Sciences
Zoi Diamantopoulou, Francesc Castro-Giner, Fabienne Dominique Schwab, Christiane Foerster, Massimo Saini, Selina Budinjas, Karin Strittmatter, Ilona Krol, Bettina Seifert, Viola Heinzelmann-Schwarz, Christian Kurzeder, Christoph Rochlitz, Marcus Vetter, Walter Paul Weber, Nicola Aceto
Summary: The generation of circulating tumor cells (CTCs) with metastatic ability is concentrated during the rest phase, and CTCs generated during the active phase lack metastatic ability. Mechanistically, the upregulation of mitotic genes during the rest phase enables CTCs' metastasis proficiency. Circadian rhythm hormones such as melatonin, testosterone and glucocorticoids dictate the generation dynamics of CTCs, and insulin promotes tumor cell proliferation in a time-dependent manner.
Article
Surgery
Judicael Hotton, Amelie Lusque, Lea Leufflen, Mario Campone, Christelle Levy, Jean-Francois Honart, Audrey Mailliez, Marc Debled, Marian Gutowski, Marianne Leheurteur, Anthony Goncalves, Clementine Jankowski, Sophie Guillermet, Thomas Bachelot, Jean-Marc Ferrero, Jean-Christophe Eymard, Thierry Petit, Nicolas Pouget, Brigitte de la Lande, Jean-Sebastien Frenel, Olivier Villacroux, Gaetane Simon, Elvire Pons-Tostivint, Frederic Marchai
Summary: The impact of local surgery performed during the year after MBC diagnosis on patients' outcomes was evaluated in a large reallife cohort. The study found that patients with MBC who received surgery within 1 year after diagnosis had significantly better overall survival and progression-free survival.
Article
Oncology
Mariana Brandao, Diogo Martins-Branco, Claudia De Angelis, Peter Vuylsteke, Richard D. Gelber, Nancy Van Damme, Lien van Walle, Arlindo R. Ferreira, Matteo Lambertini, Francesca Poggio, Didier Verhoeven, Annelore Barbeaux, Francois P. Duhoux, Hans Wildiers, Carmela Caballero, Ahmad Awada, Martine Piccart-Gebhart, Kevin Punie, Evandro de Azambuja
Summary: Among patients with de novo metastatic breast cancer who received systemic treatment and survived for nine months or more, those who underwent surgery of the primary tumor within nine months of diagnosis had longer overall survival compared to those who did not.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Yong Li, Wei-wen Li, Lin Yuan, Bo Xu
Summary: This study compared the prognosis of repeat BCS and mastectomy in patients with IBTR, finding that repeat BCS was associated with worse overall survival and breast cancer-specific survival compared to mastectomy. The estrogen receptor status of IBTR was found to be an important factor in choosing repeat BCS, and radiation therapy may improve oncological safety after repeat BCS.
Article
Multidisciplinary Sciences
Fei Tian, Shaohua Zhang, Chao Liu, Ziwei Han, Yuan Liu, Jinqi Deng, Yike Li, Xia Wu, Lili Cai, Lili Qin, Qinghua Chen, Yang Yuan, Yi Liu, Yulong Cong, Baoquan Ding, Zefei Jiang, Jiashu Sun
Summary: A thermophoretic aptasensor is utilized to profile cancer-associated proteins of extracellular vesicles (EVs) in patients' plasma, leading to the development of an EV signature capable of discriminating metastatic breast cancer, monitoring treatment response, and predicting patients' progression-free survival.
NATURE COMMUNICATIONS
(2021)
Review
Surgery
A. Kanani, T. Veen, K. Soreide
Summary: Immunotherapy has shown promising results in both early-stage and advanced colorectal cancer, with potential for changing treatment strategies and further trials.
BRITISH JOURNAL OF SURGERY
(2021)
Article
Oncology
Ana C. C. Garrido-Castro, Meredith M. M. Regan, Samuel M. M. Niman, Faina Nakhlis, Claire Remolano, Jennifer M. M. Rosenbluth, Caroline Block, Laura E. E. Warren, Jennifer R. R. Bellon, Eren Yeh, Beth T. T. Harrison, Elizabeth Troll, Nancy U. U. Lin, Sara M. M. Tolaney, Beth Overmoyer, Filipa Lynce
Summary: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, presenting as de novo metastatic disease in a significant portion of cases. Limited research has been conducted on the utilization of locoregional therapy after HER2-directed systemic therapy in these patients, as well as their locoregional progression and survival outcomes. A study identified patients with de novo HER2-positive metastatic IBC and evaluated their treatment data and outcomes. The findings suggest that surgery after systemic therapy may lead to favorable outcomes, with good locoregional control and prolonged survival observed.
Article
Surgery
Caitlin E. Marks, Samantha M. Thomas, Oluwadamilola M. Fayanju, Gayle DiLalla, Sarah Sammons, E. Shelley Hwang, Jennifer K. Plichta
Summary: The study found that all MBC patients benefited from primary tumor resection surgery. The benefit of surgery on overall survival varied across different prognostic groups.
AMERICAN JOURNAL OF SURGERY
(2022)